Pain Management

The Carisoprodol Urine Drug Test quantitatively measures levels of carisoprodol metabolite(s) in urine using highly sensitive analytical methods. This test provides precise concentration values instead of mere detection, supporting clinical monitoring, compliance evaluation, and case review. Results help distinguish trace exposure from significant use in medical or treatment settings.

The Cocaine Urine Drug Test quantitatively measures the concentration of benzoylecgonine (the primary cocaine metabolite) in urine using high-precision analytical methods. This quantitative analysis provides more than detection—it reveals the level of cocaine exposure to support clinical monitoring, compliance evaluation, or detailed case review over time.

The Cocaine Urine Drug Screen detects the presence of benzoylecgonine (a primary cocaine metabolite) in urine above threshold levels using immunoassay screening. This test serves as an initial assessment of recent cocaine use in clinical, treatment, or monitoring settings. Detection indicates use beyond cutoff but does not include confirmatory testing in this version.

The Cocaine Urine Drug Screen with Confirmation combines an initial immunoassay screen for cocaine metabolites with confirmatory testing to verify positive findings. This two-step approach ensures both detection and validation of cocaine use in urine, improving specificity and confidence of results for clinical, legal, or monitoring applications.

The Eszopiclone Urine Drug Test quantitatively measures the concentration of eszopiclone (Lunesta®) and related metabolites in urine using sensitive analytical methods. This precise test supports clinical monitoring, adherence tracking, or medication evaluation by providing actual levels rather than simply detecting presence, offering more insight into drug exposure over time.

The Fentanyl Urine Drug Test quantitatively measures the concentration of fentanyl and its metabolites in urine using advanced analytical techniques. This precise testing approach gives detailed insight into levels of fentanyl exposure, supporting clinical evaluation, treatment monitoring, and substance use analysis beyond simple detection.

The Fentanyl Urine Drug Screen detects the presence of fentanyl and its metabolites in urine above established cutoff levels using immunoassay screening methods. This test provides an initial assessment of opioid exposure, useful in clinical, monitoring, or treatment settings. A positive result indicates detection but does not include confirmatory testing.

The Fentanyl Urine Drug Screen with Confirmation performs an initial immunoassay screening for fentanyl and then applies confirmatory testing (e.g. mass spectrometry) to verify positive results. This two-step process reduces false positives and ensures specificity in detecting fentanyl use in urine for clinical or monitoring programs.

The Gabapentin Urine Drug Test quantitatively measures gabapentin levels in urine using advanced laboratory analysis. This precise assay provides actual concentration values (not just presence/absence), enabling clinicians to assess medication use, adherence, and exposure over time. It offers more detailed insight than a standard screen, helping differentiate between low-level exposure and therapeutic dosing.

The Heroin Urine Drug Test quantitatively measures levels of 6-monoacetylmorphine (6-MAM), the primary heroin metabolite, in urine using LC/MS/MS methodology. This precise analysis provides exact concentration values, offering deeper insight than a simple screen and supporting clinical monitoring, compliance review, or drug exposure evaluation over time.

The Heroin Urine Drug Screen detects the presence of heroin metabolites (such as 6-monoacetylmorphine) in urine above established cutoff levels, using immunoassay screening. This test provides a first-line assessment of recent heroin use in clinical, monitoring, or treatment settings. A positive result indicates detection but does not include confirmatory testing.

The Heroin Urine Drug Screen with Confirmation begins with an immunoassay screen for heroin metabolites (such as 6-monoacetylmorphine), then reflexes positives to mass spectrometry confirmation. This two-step approach ensures both sensitivity and specificity, validating the presence of heroin use in urine and reducing false positives for clinical or monitoring purposes.

The Marijuana Urine Drug Test quantitatively measures levels of THC metabolites (such as THC-COOH) in urine using precise analytical methods. This test provides more insight than a simple screen by reporting exact concentrations, helping clinicians monitor patterns of use, track compliance, and distinguish low-level exposure from substantial ingestion in clinical or monitoring settings.

The Marijuana Urine Drug Screen detects THC metabolites (such as THC-COOH) in urine above established cutoff levels using immunoassay screening methods. This test provides an initial indication of recent cannabis use in clinical, monitoring, or workplace settings. A positive result signals detection above threshold, but confirmatory testing is not part of this version.

The Marijuana Urine Drug Screen with Confirmation performs an initial immunoassay screen for THC metabolites (such as THC-COOH) in urine, followed by confirmatory testing to validate any positive findings. This two-step testing approach ensures both sensitivity and specificity, providing reliable confirmation of cannabis use in clinical, monitoring, or compliance settings.

The MDMA Urine Drug Screen detects the presence of MDMA (ecstasy) and related metabolites in urine above defined cutoff levels using immunoassay screening. This test offers an initial evaluation of recent MDMA use in clinical, treatment, or monitoring settings. A positive result indicates detection beyond threshold levels, but does not include confirmatory testing in this version.

The MDMA/MDA Urine Drug Test quantitatively measures concentrations of MDMA (ecstasy) and its metabolite MDA in urine using precise analytical instrumentation. This test goes beyond mere detection to report actual levels, offering clinicians and monitoring programs deeper insight into dosage, exposure trends, and compliance in drug use assessment.

The MDMA/MDA Urine Drug Screen with Confirmation begins with a broad immunoassay screen for MDMA and its metabolite MDA, then applies confirmatory testing (e.g. mass spectrometry) to validate positives. This two-step approach enhances specificity and ensures that detected substances are correctly identified, providing reliable verification of ecstasy (MDMA/MDA) use in clinical or monitoring settings.

The Meperidine Urine Drug Test quantitatively measures the concentration of meperidine and its metabolite(s) in urine using sensitive analytical methods. This precise test delivers numeric levels, enabling clinicians and monitoring programs to assess exposure, differentiate low versus significant use, and observe trends over time. It offers more insight than a simple detection screen.

The Methadone Urine Drug Test quantitatively measures the concentration of methadone and its metabolites in urine using precise analytical techniques. This detailed assay provides numeric values, offering deeper insight into methadone exposure, compliance, or therapeutic monitoring. It gives clinicians more context than a basic screen by showing how much methadone is present.

The Methadone Urine Drug Screen detects the presence of methadone metabolites in urine above defined cutoff levels using immunoassay screening methods. This test provides a first-pass assessment of methadone use in clinical, monitoring, or treatment settings. Positive results indicate detection beyond threshold limits, but no confirmatory steps are included in this test version.

The Methadone Urine Drug Screen with Confirmation begins with immunoassay screening for methadone metabolites, then applies confirmatory analysis to verify positive findings. This two-step approach enhances specificity and reduces false positives, providing reliable validation of methadone use in urine for clinical, compliance, or monitoring purposes.

The Methamphetamine D/L Isomers Urine Drug Test differentiates and quantifies both D- (dextro) and L- (levo) isomers of methamphetamine in urine using precise analytical methods. This test provides insight not just into methamphetamine presence, but into stereoisomer composition—helpful in clinical, forensic, or monitoring contexts to distinguish illicit use from prescription forms.

The Methylphenidate Urine Drug Test quantitatively measures levels of methylphenidate (Ritalin) and its metabolites in urine using advanced analytical methods to report precise concentrations. This quantitative assay helps clinicians, monitoring programs, or treatment providers track medication adherence, distinguish therapeutic use from excess, and understand dosage exposure over time.

The Mitragynine Urine Drug Test quantitatively measures mitragynine levels in urine, the principal alkaloid found in kratom, using sensitive analytical methods. This precise assay reports exact concentrations rather than just detection, giving clinicians and monitoring programs more insight into exposure, dosage trends, and user behavior over time in kratom use assessment.